人胰腺癌细胞Capan-2

  细胞系     |      2022-12-11 16:27
品牌自营品牌货号BFN60807521
规格T25培养瓶x1 1.5ml冻存管x2供货周期现货
主要用途仅供科研应用领域医疗卫生,生物产业

细胞名称

人胰腺癌细Capan-2

img1

货物编码

BFN60807521

产品规格

T25培养x1

1.5ml冻存x2

细胞数量

1x10^6

1x10^6

保存温度

37

-198

运输方式

常温保温运输

干冰运输

安全等级

1

用途限制

仅供科 2

培养体系

90%DMEM+10%FBS+1%

培养温度

37

二氧化碳浓度

5%

简介

人胰腺癌细Capan-256岁男性供体。该细胞源ATCC

注释

Part of: Cancer Cell Line Encyclopedia (CCLE) project.

Part of: COSMIC cell lines project.

Part of: NCI RAS program mutant KRAS cell line panel.

From: Memorial Sloan Kettering Cancer Center; New York; USA.

Registration: Memorial Sloan Kettering Cancer Center Office of Technology Development; SK2000-049.

Doubling time: 96 hours (PubMed=3019537); 45-60 hours (CLS); ~50-70 hours (DSMZ).

Microsatellite instability: Stable (MSS) (Sanger).

Omics: Array-based CGH.

Omics: Deep antibody staining analysis.

Omics: Deep exome analysis.

Omics: Deep proteome analysis.

Omics: Deep RNAseq analysis.

Omics: DNA methylation analysis.

Omics: Metabolome analysis.

Omics: Proteome analysis by 2D-DE/MS.

Omics: SNP array analysis.

Omics: Transcriptome analysis.

Caution: TP53 mutation indicated incorrectly as being at c.818G>A in PubMed=1630814.

Misspelling: CANPAN-2; In Cosmic 2434087.

基因突变

Heterozygous for KRAS p.Gly12Val (c.35G>T) (PubMed=8026879; PubMed=8426738; PubMed=11169959; PubMed=15367885).

TP53 p.Thr125Thr (c.375G>T); impairs TP53 splicing dramatically (PubMed=8026879; PubMed=24700732).

HLA信息

/

STR信息

Amelogenin X

CSF1PO 11,12

D3S1358 17,18

D5S818 11,12

D7S820 9,11

D8S1179 12,13

D13S317 11,12 (ATCC; CLS; Cosmic-CLP; KCLB; PubMed=25877200)

11,12,13 (DSMZ)

D16S539 9,13

D18S51 13

D21S11 31

FGA 21,24

Penta D 13,15

Penta E 11

TH01 9.3

TPOX 8

vWA 17 (ATCC; CLS; Cosmic-CLP; PubMed=25877200)

16,17 (DSMZ)

17,19 (KCLB)

参考文献

PubMed=27259358; DOI=10.1074/mcp.M116.058313

Humphrey E.S., Su S.-P., Nagrial A.M., Hochgrafe F., Pajic M., Lehrbach G.M., Parton R.G., Yap A.S., Horvath L.G., Chang D.K., Biankin A.V., Wu J., Daly R.J.

Resolution of novel pancreatic ductal adenocarcinoma subtypes by global phosphotyrosine profiling.

Mol. Cell. Proteomics 15:2671-2685(2016)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017

Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X., Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

A landscape of pharmacogenomic interactions in cancer.

Cell 166:740-754(2016)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747

Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Cancer Res. 79:1263-1273(2019)

PubMed=31037374; DOI=10.1007/s00216-019-01814-1

Lagies S., Schlimpert M., Braun L.M., Kather M., Plagge J., Erbes T., Wittel U.A., Kammerer B.

Unraveling altered RNA metabolism in pancreatic cancer cells by liquid-chromatography coupling to ion mobility mass spectrometry.

Anal. Bioanal. Chem. 411:6319-6328(2019)

PubMed=31068700; DOI=10.1038/s41586-019-1186-3

Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Nature 569:503-508(2019)

青旗(上海)生物技术发展有限公司,总部位于上海浦东新区,依托本地高校资源,逐步发展成为以生物技术为主的研发、生产、培训为一体的综合化产业平台,在标准化细胞库建立及细胞药物前端模型方面成果显著。公司生产经营原代细胞、细胞系、ELISA试剂盒、感受态细胞和HPLC检测等科研产品与服务。我们秉承对用户负责的态度,以对科研的高度严谨,以严格的质量控制,为广大生物医学科研用户提供更优质的服务!